Key result
Bucindolol reduced ventricular tachycardia or fibrillation in heart failure patients, with the effect modulated by adrenergic receptor polymorphisms.
Why the study?
Does bucindolol reduce ventricular tachycardia/ventricular fibrillation in patients with chronic heart failure and reduced LVEF, and is this effect modulated by adrenergic receptor polymorphisms?
RCT (n=1,040)
Does bucindolol reduce ventricular tachycardia/ventricular fibrillation in patients with chronic heart failure and reduced LVEF, and is this effect modulated by adrenergic receptor polymorphisms?
Answers are grounded in this paper and cite their sources.
Bucindolol reduces ventricular arrhythmias in patients with HFrEF, but this therapeutic benefit is highly dependent on β1 and α2c adrenergic receptor genetic variants.
BACKGROUND: β-blockers prevent cardiac arrhythmias in patients with chronic heart failure and reduced left ventricular ejection fraction, including ventricular tachycardia/ventricular fibrillation (VT/VF). We hypothesized that prevention of ventricular arrhythmias by the β-blocker/sympatholytic agent bucindolol is influenced by genetic variation in adrenergic receptors. METHODS AND RESULTS: From a substudy of the β-Blocker Evaluation of Survival Trial (n=1040), we identified those with the high functioning 389Arg versus the lower function 389Gly β(1) adrenergic receptor variant, and the loss of function α(2c)322-325 adrenergic receptor deletion versus the 322 to 325 wild-type (Wt)/deletion variant. VT/VF was recorded on case report forms as an adverse event. There were 493 Arg 389 β(1) receptor homozygotes (β(1)389 Arg/Arg) versus 547 Gly389 carriers and 207 α(2c)322-325 deletion carriers versus 833 homozygous Wts (α(2c)322-325 Wt/Wt). In all genotypes bucindolol was associated with a lower incidence of VT/VF (subhazard ratio, 0.42 [0.27-0.64]; P=0.00006). Bucindolol reduced VT/VF in β(1)389 Arg homozygotes (subhazard ratio, 0.26 [0.14-0.50]; P=0.00005) but not in β(1)389 Gly carriers (subhazard ratio, 0.60 [0.34-1.07]; P=0.09). For genotype combinations, the α(2c)322-325 polymorphism altered the VT/VF bucindolol response in β1389 Gly carriers, with α(2c) deletion genotypes associated with complete efficacy loss. A test of interaction was statistically significant (P=0.028) for the treatment group and a β(1)389/α(2c)322-325 three genotype construct, effectively identifying patients who exhibited enhanced response, no substantial response modification and loss of response. CONCLUSIONS: Bucindolol prevents VT/VF in subjects with heart failure and reduced left ventricular ejection fractions, and this effect is modulated by β(1)389 Arg/Gly and α(2c)322-325 Wt/deletion adrenergic receptor polymorphisms.
No takes yet. Share an insight, caveat, or question.
Aleong et al. (2012) conducted an RCT in chronic heart failure and reduced left ventricular ejection fraction (n=1,040). Bucindolol was evaluated on Ventricular tachycardia/ventricular fibrillation (VT/VF) (subhazard ratio 0.42, 95% CI 0.27-0.64, p=0.00006). Bucindolol reduced ventricular tachycardia or fibrillation in heart failure patients, with the effect modulated by adrenergic receptor polymorphisms.
Synapse has enriched 10 related papers. Consider them for comparative context: